Navigation Links
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Date:3/16/2009

any focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone-refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of operations, liquidity and capital resources, financial prospects, business objectives and strategic goals, drug development plans, timing and results of clinical trials, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the current distressed economic and financial market, Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect i
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... March 29, 2015  Three-month paliperidone palmitate, an ... compared to placebo in patients with schizophrenia, according ... this week in the Journal of ... . Results of the study served as ... (NDA) filing for three-month paliperidone palmitate injection to ...
(Date:3/27/2015)... March 27, 2015 BioCorRx, Inc. ( ... Ana, California is a healthcare solutions organization, which ... estimated at $22 billion in the U.S. alone. The Company ... FDA-approved Naltrexone in a specially compounded form for outpatient surgical ... and New Zealand ) to ...
(Date:3/27/2015)... CHAPEL HILL, N.C. , March 27, 2015 /PRNewswire/ ... function is essential to meeting challenges in clinical development, ... and face tighter regulations, the Medical Affairs function is ... charted by mature markets. According to ... market study participants have a group dedicated to Medical ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Feb. 2, 2011 WaferGen Biosystems, Inc. (OTC Bulletin ... analysis systems, today announced that it will present an overview of ... in New York City at the Waldorf Astoria Hotel, Tuesday, February ... webcast live and archived for 90 days and may be accessed ...
... 2011 Reportlinker.com announces that a new market research ... US Prebiotics Industry ... And European markets for Prebiotics in Metric Tons and ... the following product segments: Mannan-Oligosaccharide (MOS), Fructans (Fructo-Oligosaccaride (FOS), ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7
(Date:3/29/2015)... Adults who are comparing the different ... the web can now use the QuotesPros.com website for ... now be explored while researching the automated database now ... differences between what a term policy provides and what ... some men and women. Insurers typically provide base pricing ...
(Date:3/29/2015)... Telerad RxDx Multispecialty Healthcare Center, Whitefield ... on 11th January 2015. The accreditation from NABH ... comes as a true recognition of the patient ... With Telerad RxDx being the first healthcare center ... a major achievement and a significant step towards ...
(Date:3/29/2015)... March 29, 2015 The culmination of one ... coming when the Final Four invades Lucas Oil ... has been one filled with excitement, buzzer-beaters, and of course, ... busted, superstars have been made, and future professional products have ... down to the four teams that advanced through their regional ...
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... Foundation for Women’s Cancer announce today that ... 2015 recipient of the Claudia Cohen Research Foundation Prize ... presented at the Society of Gynecologic Oncology 46th Annual ... is Director of the Cedars-Sinai Women’s Cancer Program at ...
(Date:3/29/2015)... New York, NY (PRWEB) March 29, 2015 ... operators that conduct clinical trials and research, manage ... products to help their clients reach regulation standards. ... the pharmaceutical and medical device manufacturing sectors. Industry ... services, from early- to late-stage clinical research for ...
Breaking Medicine News(10 mins):Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Cheap 2015 Final Four Tickets: Ticket Down Slashes Kentucky Wildcats and Wisconsin Badgers Final Four Tickets at Lucas Oil Stadium and Issues Valuable Promo Code 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4
... Consumers need answers to questions that loom large ... is at risk.A new discussion forum launching this week ... ask tough questions and get straight answers about health ... options after a job loss."People who lose their jobs ...
... news release, Your Finances or a Facelift? It,s ... & Co Ltd over PR Newswire, we are advised ... press release was issued inadvertently. The complete, corrected release ... To DownsizeLeading Image Enhancement Coach Wendy Lewis Explains the ...
... To prevent the rejection of newly transplanted ... weaken their entire immune systems. Such potentially life-saving ... to life-threatening infections. , Now researchers at ... School of Medicine and the UNC Lineberger Comprehensive ...
... 11, 2009 "The House of Representatives and the ... ,down payment, on health care reform in the economic ... the American College of Physicians, said today. ... agreement that will provide adequate funding for critical health ...
... Feb. 11 Mesa Laboratories, Inc. (Nasdaq: ... of Directors has declared a regular quarterly cash ... stock, payable on March 16, 2009 to shareholders ... February 27, 2009.Mesa Laboratories develops, acquires, manufactures and ...
... Fresenius Kabi Pty Ltd, one of Australia,s fastest growing ... System (Robotic IV Automation) - a self-contained unit for ... Systems (IH Systems) to consolidate its IV preparation. Pharmatel ... unit in June 2009. , The RIVA System and ...
Cached Medicine News:Health News:C4CC Education Fund Launches Discussion Forum for Consumers With Health Insurance Questions 2Health News:Your Facelift or Your Finances? It's Time To Downsize 2Health News:UNC study hints at new approaches to prevent transplant rejection 2Health News:UNC study hints at new approaches to prevent transplant rejection 3Health News:ACP commends Congress for including health care reform in economic stimulus legislation 2Health News:Australia's Leading Oncology Drug Compounder Chooses RIVA System 2
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... optimize the accuracy and precision of Finnpipettes. ... widely recognized by customers throughout the world. ... the years and now covers a full ... filter tips, certified pure tips, stepper tips ...
... The easy way to order tips. Each ... tips)except for D10mL, which contains 200 tips (4 ... re-sealable Bulk Packs of 200 tips per pack. ... which can easily be opened for quick access ...
Conducting disposable tips....
Medicine Products: